Media coverage about Teladoc (NYSE:TDOC) has trended somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies positive and negative press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Teladoc earned a media sentiment score of 0.10 on Accern’s scale. Accern also assigned news stories about the health services provider an impact score of 43.6549822972953 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
These are some of the news stories that may have effected Accern’s scoring:
- Teladoc (TDOC) Coverage Initiated at Deutsche Bank (americanbankingnews.com)
- Most Shocking Stock Movements: Vornado Realty Trust (VNO), Teladoc, Inc. (TDOC) – Market Movers (financialqz.com)
- Under Analysts’ Radar: Teladoc Inc (TDOC) – ExpertGazette (expertgazette.com)
- Teladoc Scores Relative Strength Rating Upgrade (finance.yahoo.com)
- Teladoc, Inc. breached its 50 day moving average in a Bearish Manner : TDOC-US : December 7, 2017 (finance.yahoo.com)
A number of equities analysts recently issued reports on the stock. BidaskClub cut shares of Teladoc from a “hold” rating to a “sell” rating in a research note on Tuesday, August 15th. Cantor Fitzgerald reiterated a “hold” rating on shares of Teladoc in a research note on Monday, August 28th. KeyCorp reiterated a “buy” rating and issued a $37.00 price target on shares of Teladoc in a research note on Sunday, September 17th. Robert W. Baird cut shares of Teladoc from an “outperform” rating to a “neutral” rating and upped their price target for the stock from $14.00 to $36.00 in a research note on Monday, September 18th. Finally, Zacks Investment Research upgraded shares of Teladoc from a “sell” rating to a “hold” rating in a research note on Thursday, September 21st. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and ten have assigned a buy rating to the company’s stock. Teladoc currently has an average rating of “Buy” and an average price target of $39.15.
Teladoc (NYSE:TDOC) last posted its earnings results on Wednesday, November 1st. The health services provider reported ($0.55) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by ($0.25). The company had revenue of $68.70 million for the quarter, compared to the consensus estimate of $67.53 million. Teladoc had a negative net margin of 39.61% and a negative return on equity of 21.59%. Teladoc’s revenue was up 112.0% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.33) EPS. equities research analysts expect that Teladoc will post -1.57 earnings per share for the current year.
In other Teladoc news, VP Mark Hirschhorn sold 10,000 shares of the company’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $34.04, for a total transaction of $340,400.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Jason N. Gorevic sold 20,000 shares of the company’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $33.47, for a total transaction of $669,400.00. The disclosure for this sale can be found here. Insiders have sold a total of 265,000 shares of company stock worth $8,697,400 in the last 90 days. Company insiders own 4.47% of the company’s stock.
Teladoc, Inc is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company’s solution connects its Members, with its over 3,000 board certified physicians and behavioral health professionals treating a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.
Receive News & Ratings for Teladoc Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Inc and related companies with MarketBeat.com's FREE daily email newsletter.